Clinical Trial Update: Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing two 150 mg lamivudine coated tablet formulations in healthy volunteers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lamivudine (lamivudine)

Snippet

Sponsor: Universidade Federal de Pernambuco | Conditions: HIV INFECTIONS | Phase 1 | Status: COMPLETED